Could a daily blood thinner protect sick children from dangerous line clots?

NCT ID NCT07710482

First seen Jul 17, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This trial investigates whether giving a blood thinner (enoxaparin) to critically ill children with a central venous line can reduce complications like clots and blockages. About 80 children in the pediatric ICU will be randomly assigned to receive either enoxaparin or standard care. The study will track clot formation, line function, infections, and bleeding risks over 14 to 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a blood thinner called enoxaparin, given as a shot under the skin
What this could lead to
If it works, this could point toward a way to reduce dangerous blood clots and line blockages in critically ill children with central lines.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. Giving blood thinners to sick children also raises the risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTICOAGULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Menoufia university hospital, Pediatric intensive care unit

    Shibīn al Kawm, Menoufia Governorate, Egypt

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.